Brand Name :
Pentoxifylline SR, Pentoxil
Synonyms :
pentoxifylline
Class :
Hemorheologic Agents
Dosage Forms & Strengths
Tablet-ER
400mg
400
mg
orally
3 times a day
Effects may be noticed by 2-4 weeks, but it is recommended to maintain treatment for a minimum of 8 weeks
Safety and efficacy not established
Refer to adult dosing
obinutuzumab: they may increase the hypotensive effect of Blood Pressure Lowering Agents
amifostine: they may increase the hypotensive effect when combined with blood viscosity reducing agents
bromeperidol: they may decrease the hypotensive effect of blood viscosity reducing agents
ketorolac: they may increase the toxic effect of pentoxifylline
it increases the efficacy of hypotensive agents
it increases the efficacy of hypotensive agents
it increases the efficacy of hypotensive agents
it increases the efficacy of hypotensive agents
it increases the efficacy of hypotensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
it increases the effect of antiplatelet agents
it increases the effect of antiplatelet agents
it increases the effect of antiplatelet agents
it increases the effect of antiplatelet agents
it increases the effect of antiplatelet agents
blood viscosity-reducing agents: they may increase the hypotensive effect when combined with hypotension-associated agents
blood viscosity-reducing agents: they may increase the hypotensive effect when combined with hypotension-associated agents
blood viscosity-reducing agents: they may increase the hypotensive effect when combined with hypotension-associated agents
blood viscosity-reducing agents: they may increase the hypotensive effect when combined with hypotension-associated agents
blood viscosity-reducing agents: they may increase the hypotensive effect when combined with hypotension-associated agents
pentoxifylline: they may increase the hypotensive effect when combined with blood viscosity-reducing agents
pentoxifylline: they may increase the hypotensive effect when combined with blood viscosity-reducing agents
pentoxifylline: they may enhance the serum concentration of CYP1A2 Inhibitors
pentoxifylline: they may enhance the serum concentration of CYP1A2 Inhibitors
pentoxifylline: they may enhance the serum concentration of CYP1A2 Inhibitors
pentoxifylline: they may enhance the serum concentration of CYP1A2 Inhibitors
pentoxifylline: they may enhance the serum concentration of CYP1A2 Inhibitors
it increases the effect of antiplatelet agents
it increases the effect of antiplatelet agents
may have an increased anticoagulant effect when combined with heparin
maitake: they may increase the hypoglycemic effect of blood glucose lowering effects
pegvisomant: they may increase the hypoglycemic effect of Agents with blood viscosity reducing agents
quinolones: they may increase the hypoglycemic effect of agents with blood viscosity reducing agents
quinolones: they may increase the hypoglycemic effect of agents with blood viscosity reducing agents
choline magnesium trisalicylate
salicylates: they may increase the hypoglycemic effect of agents with blood viscosity reducing agents
may increase the hypotensive effect of Blood Pressure Lowering Agents
alfuzosin: they may increase the hypotensive effect when combined with blood viscosity-reducing agents
arginine: they may increase the hypotensive effect when combined with blood viscosity-reducing agents
barbiturates: they may increase the hypotensive effect when combined with blood viscoosity-reducing agents
barbiturates: they may increase the hypotensive effect when combined with blood viscoosity-reducing agents
barbiturates: they may increase the hypotensive effect when combined with blood viscoosity-reducing agents
barbiturates: they may increase the hypotensive effect when combined with blood viscoosity-reducing agents
barbiturates: they may increase the hypotensive effect when combined with blood viscoosity-reducing agents
benperidol: they may increase the hypotensive effect when combined with blood viscosity-reducing agents
brimonidine: they may increase the hypotensive effect when combined with blood viscosity-reducing agents
diazoxide: they may increase the hypotensive effect when combined with blood viscosity-reducing agents
duloxetine: may enhance the hypotensive effect when combined with blood viscosity-reducing agents
naftopidil: they may increase the hypotensive effect when combined with blood viscosity-reducing agents
nicorandil: they may increase the hypotensive effect when combined with blood viscosity-reducing agents
nitroprusside: may increase the hypotensive effect when combined with blood viscosity-lowering agents
pentoxifylline: they may increase the hypotensive effect when combined with blood viscosity-reducing agents
pholcodine: they may increase the hypotensive effect when combined with blood viscosity-lowering agents
prostacyclin analogues: they may increase the hypotensive effect when combined with blood viscosity-reducing agents
prostacyclin analogues: they may increase the hypotensive effect when combined with blood viscosity-reducing agents
prostacyclin analogues: they may increase the hypotensive effect when combined with blood viscosity-reducing agents
silodosin: they may increase the hypotensive effect when combined with blood viscosity-reducing agents
Phosphodiesterase 5 Inhibitors: they may increase the hypotensive effect when combined with blood viscosity reducing agents
Phosphodiesterase 5 Inhibitors: they may increase the hypotensive effect when combined with blood viscosity reducing agents
Phosphodiesterase 5 Inhibitors: they may increase the hypotensive effect when combined with blood viscosity reducing agents
Phosphodiesterase 5 Inhibitors: they may increase the hypotensive effect when combined with blood viscosity reducing agents
Phosphodiesterase 5 Inhibitors: they may increase the hypotensive effect when combined with blood viscosity reducing agents
monoamine oxidase inhibitors: they may increase the hypoglycemic effect of blood viscosity reducing agents
monoamine oxidase inhibitors: they may increase the hypoglycemic effect of blood viscosity reducing agents
monoamine oxidase inhibitors: they may increase the hypoglycemic effect of blood viscosity reducing agents
monoamine oxidase inhibitors: they may increase the hypoglycemic effect of blood viscosity reducing agents
monoamine oxidase inhibitors: they may increase the hypoglycemic effect of blood viscosity reducing agents
prothionamide: they may increase the hypoglycemic effect of blood viscosity reducing agents
selective serotonin reuptake inhibitors: they may increase the hypoglycemic effect of blood viscosity reducing agents
selective serotonin reuptake inhibitors: they may increase the hypoglycemic effect of blood viscosity reducing agents
selective serotonin reuptake inhibitors: they may increase the hypoglycemic effect of blood viscosity reducing agents
selective serotonin reuptake inhibitors: they may increase the hypoglycemic effect of blood viscosity reducing agents
selective serotonin reuptake inhibitors: they may increase the hypoglycemic effect of blood viscosity reducing agents
selective serotonin reuptake inhibitors (A2): they may increase the hypoglycemic effect of blood viscosity reducing agents
selective serotonin reuptake inhibitors (A2): they may increase the hypoglycemic effect of blood viscosity reducing agents
selective serotonin reuptake inhibitors (A2): they may increase the hypoglycemic effect of blood viscosity reducing agents
selective serotonin reuptake inhibitors (A2): they may increase the hypoglycemic effect of blood viscosity reducing agents
selective serotonin reuptake inhibitors (A2): they may increase the hypoglycemic effect of blood viscosity reducing agents
barbiturates: they may increase the hypotensive effect of blood viscosity reducing agents
quinagolide: they may increase the hypotensive effect of blood viscosity reducing agents
molsidomine: they may increase the hypotensive effect of blood viscosity reducing agents
Actions and Spectrum:
The main action of pentoxifylline is its ability to increase the production of a molecule called cAMP, which helps to relax blood vessels and improve blood flow. This action makes it useful in treating conditions such as peripheral artery disease and intermittent claudication, which are characterized by reduced blood flow to the limbs.
pentoxifylline has a relatively narrow spectrum of action and is primarily used to treat circulation problems and improve blood flow in the legs and feet. It has also been used off-label to treat certain other conditions, such as liver cirrhosis, but its use for these purposes is not supported by strong scientific evidence.
Frequency Defined
1-10%
Vomiting
Nausea
<1%
Anaphylaxis
Angina
Anorexia
Pancytopenia
Aplastic anemia
Conjunctivitis
Aseptic meningitis
Angioedema
Chest pain
Leukopenia
Leukemia
Black Box Warning
Pentoxifylline carries a black box warning from the U.S. Food and Drug Administration (FDA) regarding the risk of serious liver injury.
Contraindication/Caution:
Contraindications:
Cautions:
Pregnancy warnings:
US FDA pregnancy category: C
Lactation:
Excreted into human milk is known
Pregnancy Categories:
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.
Category B: There were lack of studies on pregnant women and no evidence of risk to the foetus in animal experiments.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology:
pentoxifylline is a medication that belongs to the class of drugs called methylxanthines. It is used to improve blood flow in patients with circulation problems, such as peripheral artery disease and claudication.
Pharmacodynamics:
The exact mechanism of action of pentoxifylline is not fully understood, but it is thought to work by reducing the viscosity of blood and decreasing the thickness of red blood cells, thereby improving blood flow and oxygen delivery to tissues. It may also have anti-inflammatory effects, which can help to relieve symptoms associated with circulation problems.
Pharmacokinetics:
Absorption
pentoxifylline is a medication used to improve blood flow and is absorbed rapidly when taken orally
Distribution
It has a bioavailability of approximately 50-70%
Metabolism
metabolized in the liver by CYP2C9 and CYP2D6 enzymes.
Elimination and Excretion
majority of the drug is eliminated in the urine, either as unchanged drug or as metabolites.
Administration:
Oral administration
pentoxifylline is typically administered orally, in the form of a tablet, three to four times daily with food. The recommended starting dose may vary depending on the patient’s condition and response to the medication.
It is important to follow the dosing instructions provided by your healthcare provider and not to alter the dose without their approval. Additionally, it is recommended to take pentoxifylline with food to minimize the risk of side effects such as stomach upset.
Patient information leaflet
Generic Name: pentoxifylline
Why do we use pentoxifylline?
pentoxifylline is used to improve blood flow in individuals with circulation problems, particularly in those with peripheral artery disease (PAD) or intermittent claudication (leg pain caused by reduced blood flow).
It works by decreasing the thickness (viscosity) of the blood, making it easier for the blood to flow through narrowed or blocked arteries. Additionally, pentoxifylline has been used to treat other conditions such as liver disease and skin disorders, although its use for these conditions is less well established.